Kyntheum

Brodalumab, the active ingredient in Kyntheum, is an IL‑17 receptor A antagonist presented as a subcutaneous solution for subcutaneous use. It is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who require systemic therapy. It is administered by healthcare professionals under medical supervision, with dosing individualized based on disease severity and patient response.

GNH USA supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable cold‑chain logistics for biologic products.

Kyntheum (brodalumab) targets the IL‑17 signaling pathway, a key driver of inflammatory skin disease.

Plaque psoriasis (moderate to severe): reduces skin lesions and improves PASI scores. Psoriasis vulgaris (severe): achieves higher rates of clear or almost clear skin. Chronic plaque psoriasis: provides sustained disease control over long‑term treatment.

Brodalumab may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis - Upper respiratory tract infection - Headache - Injection site reactions

Serious or Rare Side Effects: - Suicidal ideation or behavior - Serious infections (e.g., cellulitis, pneumonia) - Neutropenia

When prescribing brodalumab, clinicians should observe several precautionary measures to ensure patient safety.

Screen for suicidal ideation: monitor patients for mood changes and depression throughout therapy. Assess infection risk: avoid initiating treatment in patients with active serious infections. Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. Live vaccines: contraindicated during treatment; administer before starting therapy. Discontinue if serious adverse events occur: follow prescriber guidance and report to pharmacovigilance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Brodalumab can interact with other agents, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Live attenuated vaccines: may cause severe infection; avoid concurrent use. - Concurrent IL‑17 pathway inhibitors: additive immunosuppression; avoid combination.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may increase infection risk; monitor patient. - Methotrexate: potential additive immunosuppression; monitor labs. - Cyclosporine: may affect renal function; monitor kidney parameters.